Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
Paul M. Ridker,Brendan M. Everett,Tom Thuren,Jean G. MacFadyen,William Chang,Christie M. Ballantyne,Francisco H. Fonseca,Jose C. Nicolau,Wolfgang Koenig,Stefan D. Anker,John J.P. Kastelein,Jan H. Cornel,Prem Pais,Daniel Pella,Jacques Genest,Renata Cifkova,Alberto J. Lorenzatti,Tamás Forster,Zhanna Kobalava,Luminita Vida-Simiti,Marcus Flather,Hiroaki Shimokawa,Hisao Ogawa,Mikael Dellborg,Paulo Roberto Ferreira Rossi,Roland P.T. Troquay,Peter Libby,Robert J. Glynn +27 more
TLDR
Antiinflammatory therapy targeting the interleukin‐1β innate immunity pathway with canakinumab at a dose of 150 mg every 3 months led to a significantly lower rate of recurrent cardiovascular events than placebo, independent of lipid‐level lowering.Abstract:
BackgroundExperimental and clinical data suggest that reducing inflammation without affecting lipid levels may reduce the risk of cardiovascular disease. Yet, the inflammatory hypothesis of atherothrombosis has remained unproved. MethodsWe conducted a randomized, double-blind trial of canakinumab, a therapeutic monoclonal antibody targeting interleukin-1β, involving 10,061 patients with previous myocardial infarction and a high-sensitivity C-reactive protein level of 2 mg or more per liter. The trial compared three doses of canakinumab (50 mg, 150 mg, and 300 mg, administered subcutaneously every 3 months) with placebo. The primary efficacy end point was nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death. ResultsAt 48 months, the median reduction from baseline in the high-sensitivity C-reactive protein level was 26 percentage points greater in the group that received the 50-mg dose of canakinumab, 37 percentage points greater in the 150-mg group, and 41 percentage points greater in t...read more
Citations
More filters
Journal ArticleDOI
2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular riskThe Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)
François Mach,Colin Baigent,Alberico L. Catapano,Konstantinos C. Koskinas,Manuela Casula,Lina Badimon,M. John Chapman,Guy De Backer,Victoria Delgado,Brian A. Ference,Ian D. Graham,Alison Halliday,Ulf Landmesser,Borislava Mihaylova,Terje R. Pedersen,Gabriele Riccardi,Dimitrios J. Richter,Marc S. Sabatine,Marja-Riitta Taskinen,Lale Tokgozoglu,Olov Wiklund,Christian Mueller,Heinz Drexel,Victor Aboyans,Alberto Corsini,Wolfram Doehner,Michel Farnier,Bruna Gigante,Meral Kayıkçıoğlu,Goran Krstacic,Ekaterini Lambrinou,Basil S. Lewis,Josep Masip,Philippe Moulin,Steffen E. Petersen,Anna Sonia Petronio,Massimo F Piepoli,Xavier Pintó,Lorenz Räber,Kausik K. Ray,Željko Reiner,Walter F Riesen,Marco Roffi,Jean-Paul Schmid,Evgeny Shlyakhto,Iain A. Simpson,Erik S.G. Stroes,Isabella Sudano,Alexandros D Tselepis,Margus Viigimaa,Cecile Vindis,Alexander Vonbank,Michal Vrablik,Mislav Vrsalovic,José Luis Zamorano,Jean-Philippe Collet,Stephan Windecker,Veronica Dean,Donna Fitzsimons,Chris P Gale,Diederick E. Grobbee,Sigrun Halvorsen,Gerhard Hindricks,Bernard Iung,Peter Jüni,Hugo A. Katus,Christophe Leclercq,Maddalena Lettino,Béla Merkely,Miguel Sousa-Uva,Rhian M. Touyz,Djamaleddine Nibouche,Parounak H. Zelveian,Peter Siostrzonek,Ruslan Najafov,Philippe van de Borne,Belma Pojskic,Arman Postadzhiyan,Lambros Kypris,Jindřich Špinar,Mogens Lytken Larsen,Hesham Salah Eldin,Timo E. Strandberg,Jean Ferrières,Rusudan Agladze,Ulrich Laufs,Loukianos S. Rallidis,Laszlo Bajnok,Thorbjorn Gudjonsson,Vincent Maher,Yaakov Henkin,Michele Massimo Gulizia,Aisulu Mussagaliyeva,Gani Bajraktari,Alina Kerimkulova,Gustavs Latkovskis,Omar Hamoui,Rimvydas Šlapikas,Laurent Visser,P. Dingli,Victoria Ivanov,Aneta Boskovic,Mbarek Nazzi,Frank L.J. Visseren,Irena Mitevska,Kjetil Retterstøl,Piotr Jankowski,Ricardo Fontes-Carvalho,Dan Gaita,Marat V. Ezhov,Marina Foscoli,Vojislav Giga,Daniel Pella,Zlatko Fras,Leopoldo Pérez de Isla,Emil Hagström,Roger Lehmann,Leila Abid,Oner Ozdogan,Olena Mitchenko,Riyaz S. Patel +120 more
Journal ArticleDOI
2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk
Alison Halliday,Colin Baigent,François Mach,Borislava Mihaylova,Borislava Mihaylova,Brian A. Ference +5 more
TL;DR: Authors/Task Force Members (François Macha, Colin Baigentb,∗∗,2, Alberico L. Catapanoc), ESC Committee for Practice Guidelines (CPG) (Stephan Windeckeraa), ESC National Cardiac Societies (Djamaleddine Nibouchean, Parounak H. Patelcl)
Journal ArticleDOI
Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
Deepak L. Bhatt,P. Gabriel Steg,Michael Miller,Eliot A. Brinton,Terry A. Jacobson,Steven B. Ketchum,Ralph T. Doyle,Rebecca A. Juliano,Lixia Jiao,Craig Granowitz,Jean-Claude Tardif,Christie M. Ballantyne,Reduce-It Investigators +12 more
TL;DR: Among patients with elevated triglyceride levels despite the use of statins, the risk of ischemic events, including cardiovascular death, was significantly lower among those who received 2 g of icosapent ethyl twice daily than amongThose who received placebo.
Journal ArticleDOI
Chronic inflammation in the etiology of disease across the life span
David Furman,Judith Campisi,Judith Campisi,Eric Verdin,Pedro Carrera-Bastos,Sasha Targ,Claudio Franceschi,Luigi Ferrucci,Derek W. Gilroy,Alessio Fasano,Gary W. Miller,Andrew H. Miller,Alberto Mantovani,Alberto Mantovani,Alberto Mantovani,Cornelia M. Weyand,Nir Barzilai,Jorge Goronzy,Thomas A. Rando,Thomas A. Rando,Rita B. Effros,Alejandro Lucia,Nicole Kleinstreuer,George M. Slavich +23 more
TL;DR: The multi-level mechanisms underlying SCI and several risk factors that promote this health-damaging phenotype, including infections, physical inactivity, poor diet, environmental and industrial toxicants and psychological stress are described.
Journal ArticleDOI
2021 ESC Guidelines on cardiovascular disease prevention in clinical practice
Frank L.J. Visseren,François Mach,Yvo M. Smulders,David Carballo,Konstantinos C. Koskinas,Maria Bäck,Athanase Benetos,Alessandro Biffi,José-Manuel Boavida,Davide Capodanno,Bernard Cosyns,Carolyn Crawford,Constantinos H. Davos,Ileana Desormais,Emanuele Di Angelantonio,Oscar H. Franco,Sigrun Halvorsen,FD Richard Hobbs,Monika Hollander,Ewa A. Jankowska,Matthias Michal,Simona Sacco,Naveed Sattar,Lale Tokgozoglu,Serena Tonstad,Konstantinos P Tsioufis,Ineke van Dis,Isabelle C. Van Gelder,Christoph Wanner,Bryan Williams,Guy De Backer,Vera Regitz-Zagrosek,Anne Hege Aamodt,Magdy Abdelhamid,Victor Aboyans,Christian Albus,Riccardo Asteggiano,Magnus Bäck,Michael A. Borger,Carlos Brotons,Jelena Čelutkienė,Renata Cifkova,Maja Čikeš,Francesco Cosentino,Nikolaos Dagres,Tine De Backer,Dirk De Bacquer,Victoria Delgado,Hester Den Ruijter,Paul Dendale,Heinz Drexel,Volkmar Falk,Laurent Fauchier,Brian A. Ference,Jean Ferrières,Marc Ferrini,Miles Fisher,Danilo Fliser,Zlatko Fras,Dan Gaita,Simona Giampaoli,Stephan Gielen,Ian D. Graham,Catriona Jennings,Torben Jørgensen,Alexandra Kautzky-Willer,Maryam Kavousi,Wolfgang Koenig,Aleksandra Konradi,Dipak Kotecha,Ulf Landmesser,Madalena Lettino,Basil S. Lewis,Aleš Linhart,Maja-Lisa Løchen,Konstantinos Makrilakis,Giuseppe Mancia,Pedro Marques-Vidal,John W. McEvoy,Paul McGreavy,Béla Merkely,Lis Neubeck,Jens Cosedis Nielsen,Joep Perk,Steffen E. Petersen,Anna Sonia Petronio,Massimo F Piepoli,Nana Pogosova,Eva Prescott,Kausik K. Ray,Zeljko Reiner,Dimitrios J. Richter,Lars Rydén,Evgeny Shlyakhto,Marta Sitges,Miguel Sousa-Uva,Isabella Sudano,Monica Tiberi,Rhian M. Touyz,Andrea Ungar,W. M. Monique Verschuren,Olov Wiklund,David A. Wood,José Luis Zamorano,Carolyn A Crawford,Oscar H Franco Duran +105 more
References
More filters
Journal ArticleDOI
Atherosclerosis — An Inflammatory Disease
TL;DR: Atherosclerosis is an inflammatory disease as discussed by the authors, and it is a major cause of death in the United States, Europe, and much of Asia, despite changes in lifestyle and use of new pharmacologic approaches to lower plasma cholesterol concentrations.
Journal ArticleDOI
Immunity, Inflammation, and Cancer
TL;DR: The principal mechanisms that govern the effects of inflammation and immunity on tumor development are outlined and attractive new targets for cancer therapy and prevention are discussed.
Journal ArticleDOI
Inflammation, Atherosclerosis, and Coronary Artery Disease
TL;DR: The evidence is recounted that atherosclerosis, the main cause of CAD, is an inflammatory disease in which immune mechanisms interact with metabolic risk factors to initiate, propagate, and activate lesions in the arterial tree.
Journal ArticleDOI
C-Reactive Protein and Other Markers of Inflammation in the Prediction of Cardiovascular Disease in Women
TL;DR: The addition of the measurement of C-reactive protein to screening based on lipid levels may provide an improved method of identifying persons at risk for cardiovascular events.
Related Papers (5)
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals
Peter Duewell,Hajime Kono,Katey J. Rayner,Katey J. Rayner,Cherilyn M. Sirois,Gregory I. Vladimer,Franz Bauernfeind,George S. Abela,Luigi Franchi,Guillermo Gabriel Nuñez,Max Schnurr,Terje Espevik,Egil Lien,Katherine A. Fitzgerald,Kenneth L. Rock,Kathryn J. Moore,Kathryn J. Moore,Samuel D. Wright,Veit Hornung,Eicke Latz,Eicke Latz +20 more